Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
HomePosted by cnhnewcorpdev
Press Release

ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026

cnhnewcorpdev
April 15, 2026
Press Release

ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests

cnhnewcorpdev
March 18, 2026
Press Release

ClearNote Health’s Enhanced Avantect® Pancreatic Cancer Test Delivers Industry-Leading Early Detection Performance

cnhnewcorpdev
February 23, 2026
Company News Press Release

ClearNote Health to Showcase Latest Advancements in Early Cancer Detection Testing at ESMO Congress 2025

cnhnewcorpdev
October 17, 2025
Event

ESMO | Oct 17-21, 2025 | Berlin, Germany

cnhnewcorpdev
October 17, 2025
Company News Press Release

ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test

cnhnewcorpdev
September 25, 2025
Event

17th Annual Next Generation Summit | Aug 18-20, 2025 | Washington, D.C.

cnhnewcorpdev
July 29, 2025
Event

15th Annual World Biomarker & CDx Summit | September 22-25, 2025 | Boston, MA

cnhnewcorpdev
July 16, 2025
Company News Press Release

ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test

cnhnewcorpdev
July 9, 2025
Company News Press Release

ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients

cnhnewcorpdev
June 16, 2025

Posts pagination

1 2 3 4 5

Meet Us at ASCO 2026

ClearNote Health
May 28, 2026

ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

ClearNote Health
May 27, 2026

Follow us
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures. The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria.

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences